Treatment satisfaction and goal attainment with onabotulinumtoxinA in patients with incontinence due to idiopathic OAB Journal Article


Authors: Brubaker, L; Gousse, A.; Sand, P.; Thompson, C; Patel, V.; Zhou, J; Jenkins, B.; Sievert, K. D.
Article Title: Treatment satisfaction and goal attainment with onabotulinumtoxinA in patients with incontinence due to idiopathic OAB
Abstract: INTRODUCTION AND HYPOTHESIS: Clinically meaningful overactive bladder syndrome (OAB) symptom relief is associated with patient satisfaction. This study evaluated the effects of onabotulinumtoxinA on patient satisfaction and goal attainment. METHODS: In a 36-week, multicenter, double-blind study, 313 participants with idiopathic OAB and urinary urgency incontinence inadequately managed with anticholinergics were randomized to placebo or one of five onabotulinumtoxinA doses. Assessment included a modified OAB-Patient Satisfaction with Treatment Questionnaire (PSTQ) and four Patient Global Assessment questions assessed changes in symptoms, quality of life, activity limitations, and emotions. RESULTS: Mean changes from baseline in OAB-PSTQ scores for the main module (Q2-Q13) at week 12 were greater for each onabotulinumtoxinA group (range, -31.5% to -48.9%) versus placebo (-17.6%). Greater proportions of patients in onabotulinumtoxinA groups attained their primary goal (range, 34.5% to 65.3%) versus placebo (23.7%). CONCLUSIONS: Patients with OAB are more likely to be satisfied and/or achieve their primary treatment goal with onabotulinumtoxinA treatment than with placebo, consistent with symptom improvements.
Keywords: Female; Humans; Middle Aged; Obstetrics and Gynecology; Male; Treatment Outcome; Activities of Daily Living; Botulinum Toxins, Type A/therapeutic use; Double-Blind Method; Patient Satisfaction; Quality of Life/psychology; Questionnaires; Urinary Bladder, Overactive/complications; Urinary Incontinence/drug therapy/etiology/psychology
Journal Title: International Urogynecology Journal
Volume: 23
Issue: 8
ISSN: 0937-3462
Publisher: Unknown  
Journal Place: England
Date Published: 2012
Start Page: 1017
End Page: 1025
Language: eng
DOI/URL:
Notes: JID: 101567041; 0 (onabotulinumtoxinA); EC 3.4.24.69 (Botulinum Toxins, Type A); 2011/09/28 [received]; 2011/12/24 [accepted]; 2012/01/25 [aheadofprint]; ppublish